EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Patient Acceptability of Partial Enteral Nutrition as a Concomitant Therapy to Adalimumab in Adults with Active Crohn’s Disease: BIOPIC Trial

Catarina Fandinga, Jennifer Clowe, Bernadette White, Iona Campbell, John Paul Seenan, Emily Brownson, Simon Milling, Athanasios Koutsos, Gwo-Tzer Ho, Craig Mowat, Elaine Robertson, Daniel R Gaya und 4 weitere

Annals of Nutrition and Metabolism · 19.05.2026 · 1-9

DOI: 10.1159/000551940 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Nutrition and Metabolism, online erschienen am 19.05.2026. Verfasst von Catarina Fandinga und 15 weiteren Autor:innen. Beteiligte Einrichtung: Human Nutrition, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. Hauptthemen laut MEDLINE: Crohn Disease, Enteral Nutrition, Adalimumab, Patient Acceptance of Health Care. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Partial enteral nutrition (PEN) is a dietary therapy for the management of Crohn’s disease (CD). Although considered less restrictive than exclusive enteral nutrition, there are scarce data from patients with lived experience to support PEN. This study assessed dietary intake, the acceptability, and adherence to 50% PEN alongside treatment with adalimumab, for 6 weeks, in adults with active CD.

Methods

Adherence to PEN was measured by three methods: an interview with a dietitian using an adherence questionnaire, dietary analysis from food diaries, and inventory from provided enteral nutrition formula and unused stock returned. Food diaries were also used to assess differences in intake between participants receiving 50% PEN (ADA + PEN group) and those who did not (ADA group).

Results

Twenty-nine of 41 patients (71%) took the PEN volume prescribed every day for 6 weeks; 39 (95%) met the full PEN volume prescribed for 5 weeks or more. Fifty-nine percent reported no issues adhering to PEN, 11.5% felt too full, 10.5% reported social life constraints, and 5% taste fatigue. Most respondents would use PEN again to manage CD (93%). Food-diary analysis also showed high level of adherence (median [IQR] daily energy intake provided by PEN: 53% [49; 71.2]). The median (IQR) percentage of enteral feed used from the volume provided was 96% (88; 101). Participants in the ADA + PEN group modified the unrestricted portion of their diet, particularly dinners.

Conclusion

These results support the good acceptability rate of 50% PEN alongside treatment with adalimumab, emphasizing its potential of being a viable dietary treatment option for adults with CD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseEnteral NutritionAdalimumabPatient Acceptance of Health CareAnti-Inflammatory AgentsHumansAdultFemaleMaleMiddle AgedPatient ComplianceSurveys and QuestionnairesYoung AdultCombined Modality TherapyDiet Records

Stichwörter der Autor:innen

AdherenceCrohn’s diseasePartial enteral nutrition

Substanzen

AdalimumabAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Human Nutrition, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
  • Department of Gastroenterology, Gartnavel General Hospital, Glasgow, UK.
  • School of Infection and Immunity, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK.
  • Department of Gastroenterology, Ninewells Hospital, Dundee, UK.
  • Department of Gastroenterology, University Hospital Hairmyres, East Kilbride, UK.
  • Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK.

Zitieren

APA

Fandinga, C., Clowe, J., White, B., Campbell, I., Seenan, J. P., Brownson, E., Milling, S., Koutsos, A., Ho, G. T., Mowat, C., Robertson, E., Gaya, D. R., Kefayat, A., Din, S., MacDonald, J., & Gerasimidis, K. (2026). Patient Acceptability of Partial Enteral Nutrition as a Concomitant Therapy to Adalimumab in Adults with Active Crohn’s Disease: BIOPIC Trial. Annals of Nutrition and Metabolism, 1-9. https://doi.org/10.1159/000551940

Vancouver

Fandinga C, Clowe J, White B, Campbell I, Seenan JP, Brownson E, et al. Patient Acceptability of Partial Enteral Nutrition as a Concomitant Therapy to Adalimumab in Adults with Active Crohn’s Disease: BIOPIC Trial. Annals of Nutrition and Metabolism. 2026:1-9. doi:10.1159/000551940

BibTeX
@article{Fandinga2026,
  author = {Fandinga, Catarina and Clowe, Jennifer and White, Bernadette and Campbell, Iona and Seenan, John Paul and Brownson, Emily and Milling, Simon and Koutsos, Athanasios and Ho, Gwo-Tzer and Mowat, Craig and Robertson, Elaine and Gaya, Daniel R and Kefayat, Amirhosein and Din, Shahida and MacDonald, Jonathan and Gerasimidis, Konstantinos},
  title = {Patient Acceptability of Partial Enteral Nutrition as a Concomitant Therapy to Adalimumab in Adults with Active Crohn’s Disease: BIOPIC Trial},
  journal = {Annals of Nutrition and Metabolism},
  year = {2026},
  pages = {1--9},
  doi = {10.1159/000551940}
}
Kostenlos starten →